NEW AND UNUSUAL MODALITIES:
When the Mold Does Not Fit—New Biologics and Modalities

COVID LEARNINGS:
Crisis-Driven Efficiency and Innovation

NEW AND UNUSUAL MODALITIES:
When the Mold Does Not Fit—New Biologics and Modalities

WELL-CHARACTERIZED BIOLOGICALS AND BIOSIMILARS;
POST-LICENSURE ISSUES
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRACK-BASED PROGRAMMING</td>
<td>3</td>
</tr>
<tr>
<td>Covid Learnings</td>
<td>3</td>
</tr>
<tr>
<td>New and Unusual Modalities</td>
<td>3</td>
</tr>
<tr>
<td>Well-Characterized Biologicals and Biosimilars; Post-Licensure Issues</td>
<td>3</td>
</tr>
<tr>
<td>IMPORTANT ABSTRACT DATES</td>
<td>4</td>
</tr>
<tr>
<td>Poster Abstract Submissions</td>
<td>4</td>
</tr>
<tr>
<td>ABSTRACT AND POSTER POLICY</td>
<td>5</td>
</tr>
<tr>
<td>Permissions/Clearances</td>
<td>5</td>
</tr>
<tr>
<td>Registration Requirement for Participation and Publication</td>
<td>5</td>
</tr>
<tr>
<td>Posters Must Include the Accepted Abstract</td>
<td>5</td>
</tr>
<tr>
<td>ABSTRACT FORMAT</td>
<td>6</td>
</tr>
<tr>
<td>Abstract Length and Images</td>
<td>6</td>
</tr>
<tr>
<td>Acceptance Criteria</td>
<td>6</td>
</tr>
<tr>
<td>Rejections</td>
<td>6</td>
</tr>
<tr>
<td>Encore Presentations</td>
<td>7</td>
</tr>
<tr>
<td>Abstract Revisions</td>
<td>7</td>
</tr>
<tr>
<td>Notification of Receipt and Verification of Submission</td>
<td>7</td>
</tr>
<tr>
<td>SCREENING PROCESS</td>
<td>8</td>
</tr>
<tr>
<td>Appeals</td>
<td>8</td>
</tr>
<tr>
<td>Registration Requirement</td>
<td>9</td>
</tr>
<tr>
<td>Change in Presenting Author</td>
<td>9</td>
</tr>
<tr>
<td>Poster Schedule</td>
<td>9</td>
</tr>
<tr>
<td>Cancellation Policy and Substitution</td>
<td>9</td>
</tr>
<tr>
<td>Abstract/Poster Withdrawal</td>
<td>9</td>
</tr>
<tr>
<td>POSTER REQUIREMENTS</td>
<td>10</td>
</tr>
<tr>
<td>FREQUENTLY ASKED QUESTIONS</td>
<td>10</td>
</tr>
<tr>
<td>POSTER ABSTRACT TRACKS/THEMES/KEYWORDS</td>
<td>11</td>
</tr>
</tbody>
</table>
**TRACK-BASED PROGRAMMING**

Each abstract proposal must relate to one of the program’s three tracks.

<table>
<thead>
<tr>
<th>TRACK 1</th>
<th>TRACK 2</th>
<th>TRACK 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COVID LEARNINGS:</strong> Crisis-Driven Efficiency and Innovation</td>
<td><strong>NEW AND UNUSUAL MODALITIES:</strong> When the Mold Does Not Fit—New Biologics and Modalities</td>
<td><strong>WELL-CHARACTERIZED BIOLOGICALS AND BIOSIMILARS; POST-LICENSE ISSUE</strong></td>
</tr>
<tr>
<td><strong>THEME 1:</strong> Speed to Patient</td>
<td><strong>THEME 1:</strong> Gene Therapies, Gene Editing, CAR-T</td>
<td><strong>THEME 1:</strong> Vaccines</td>
</tr>
<tr>
<td><strong>THEME 2:</strong> Managing Collateral Damage</td>
<td><strong>THEME 2:</strong> Cell Therapies, Complex and Combination Products</td>
<td><strong>THEME 2:</strong> Biosimilars, Interchangeable Biologics, and Well-Characterized Products</td>
</tr>
<tr>
<td><strong>THEME 3:</strong> Clinical Trial Design, Execution, and Associated Disciplines at Crisis Pace</td>
<td><strong>THEME 3:</strong> Drug/Device, Patient-Individualized Approaches</td>
<td><strong>THEME 3:</strong> New Assays Raise Questions About the Products We Thought We Knew</td>
</tr>
</tbody>
</table>

**COVID LEARNINGS:**

- Crisis-Driven Efficiency and Innovation

**NEW AND UNUSUAL MODALITIES:**

- When the Mold Does Not Fit—New Biologics and Modalities

**WELL-CHARACTERIZED BIOLOGICALS AND BIOSIMILARS; POST-LICENSE ISSUE:**

- Vaccines
- Biosimilars, Interchangeable Biologics, and Well-Characterized Products
- New Assays Raise Questions About the Products We Thought We Knew
IMPORTANT
ABSTRACT DATES

ALL DATES SUBJECT TO CHANGE

POSTER ABSTRACT SUBMISSIONS

- **EARLY DECEMBER 2021**
  Submission site opens

- **FEBRUARY 9, 2022 AT 5 PM ET**
  DEADLINE: Poster abstract submission site closes

- **WEEK OF MARCH 7, 2022**
  Abstract Accept/Reject notifications sent

- **MARCH 24, 2022**
  DEADLINE: Poster Presenting Author Registration

- **WEEK OF MARCH 28, 2022**
  Authors begin uploading completed posters

- **WEEK OF MARCH 28, 2022**
  Schedule notifications sent

- **APRIL 13, 2022**
  Deadline for uploading posters

- **MAY 9-12, 2022**
  NBC takes place
ABSTRACT AND POSTER POLICY

By submitting an abstract for presentation at the AAPS National Biotechnology Conference, you agree to abide by the conditions and policies provided below, as well as the decisions of the NBC Abstract Screening Committee and AAPS staff.

Direct questions about this (NBC) policy to abstracts@aaps.org.

PERMISSIONS/CLEARANCES

AAPS recommends the designated presenting author submit the abstract. The submitter is responsible for obtaining the necessary permissions and clearances for all research, information, and graphics used in both the abstract and the poster, and will receive all abstract/poster-related communications up to accept/reject notifications. Once an abstract is accepted, the designated presenting author receives all abstract and poster-related communications. AAPS assumes no liability or responsibility for the publication of any material that is submitted.

Use of the AAPS logo in any abstract submission or poster presentation is STRICTLY PROHIBITED.

REGISTRATION REQUIREMENT FOR PARTICIPATION AND PUBLICATION

The presenting author is required to participate in the meeting to have the poster included in the collection. If the presenting author is unable to participate during the meeting, a coauthor is required to assume the responsibilities of the presenting author and represent the poster. If no authors are able to participate in the meeting, a presenter may be appointed who is not an author of the abstract.

The presenter or presenting author is required to register either as a full-conference, one-day, exhibitor, or exhibit-hall-only attendee for the meeting by the presenting author registration deadline, or AAPS will withdraw the abstract/poster. Withdrawn abstracts/posters will not be published online or included in the poster collection.

Exhibitors who are presenters or presenting authors must complete their registrations by the presenting author registration deadline, even if they are using an exhibitor registration provided by their employer.

POSTERS MUST INCLUDE THE ACCEPTED ABSTRACT

Posters that are uploaded for presentation must include the accepted abstract, including all methods used and data resulting from the research. The title of the poster must match, verbatim, the title of the accepted abstract.

Omitting data from a poster presentation that was included in the submitted abstract is unethical. Authors and organizations violating these requirements will be subject to penalties including withdrawal of their paper and their being barred from submitting to any future AAPS meeting.

ABSTRACTS MUST BE SUBMITTED TO THE SUBMISSION WEBSITE BY 5:00 PM ET ON THE INDICATED DEADLINE DATE.

Abstracts submitted after this deadline or by different means will be rejected without review.

DATA SUPPORTING THE CONCLUSION OF THE ABSTRACT MUST BE DEVELOPED PRIOR TO SUBMISSION.

Abstracts stating that data will be developed between the time of submission and the time of the meeting will be rejected without review.

USE THE GOOGLE CHROME BROWSER TO SUBMIT YOUR ABSTRACT.

The submission site is not compatible with Microsoft Edge/Internet Explorer as well as some other browsers.

The submission system can be accessed at the Submission Site.

To ensure receipt of all abstract-related correspondence, add the following addresses to your contact list:
support@conferenceabstracts.com
scorecard@cadmiumcd.com
abstracts@aaps.org
homricht@aaps.org
appeals@aaps.org
posters@aaps.org
ACCEPTANCE CRITERIA
Acceptance of the abstract for poster presentation will be based on the concise, accurate presentation of new data. It is imperative that data is presented in the Results section so that AAPS scientific screeners can judge the scientific value of your abstract. Include all research information, data, charts, and graphs in your submission so that it can be screened in its entirety. Abstracts will be reviewed and scored based on the following:

- Is the CONCLUSION of the research data driven?
- How EXCITING/NOVEL will viewers find this research?
- How well does the RESEARCH incrementally advance its field?
- How well does the author’s selected strategy for evaluating the HYPOTHESIS suit the project?

REJECTIONS
AAPS reviews each abstract to ensure it is qualified for consideration. Abstracts that do not meet the requirements outlined above are rejected. Causes for rejection include:

- Lack of data.
- Acknowledgements were included in the abstract, preventing a blind review.
- Affiliation or company name(s) were included in the abstract, preventing a blind review (product names are permitted).
- Commerciality.
- Inconsistent or ambiguous data.
- Reviews of literature.
- Lack of novelty or innovation.
- Stating that data or information will be included in the poster presentation.
- Previously published research.
- Including previously published information in your research without referencing the information in the abstract submission.
- Failure to follow format guidelines (Purpose, Methods, Results, Conclusion, References, Acknowledgements).
- Failure to upload tables or charts (if used) as images as directed. Tables and/or charts are not to be included in the text box for the Purpose, Methods, Results, or Conclusion. Tables and/or charts must be uploaded as images—refer to the Abstract Format section above.
- Failure to submit one strong abstract instead of several abstracts presenting the same work. The submission of multiple abstracts covering the same or similar work is discouraged and may be rejected by the committee.

ABSTRACT FORMAT

DATA, including all research information either in paragraph format or in charts and graphs. AAPS rejects any abstract that is not based on data.

TITLE in headline style: 200-character limit with no period at the end

AUTHORS: Limit of 13 authors

PURPOSE: paragraph format

METHODS: paragraph format

RESULTS: paragraph format

CONCLUSIONS: paragraph format

REFERENCES: Reference any previously published material used in your research.

IMAGES in jpg format. Do not include images in the Purpose, Methods, Results, or Conclusion sections.

TABLES AND/OR CHARTS:
Do not include tables or charts in the Purpose, Methods, Results, or Conclusion sections. These should be converted to an image and uploaded in the Images section (3 images are allowed).

ACKNOWLEDGEMENTS, DISCLAIMERS, FUNDING, AND OTHER DISCLOSURE OR CONFLICT OF INTEREST STATEMENTS:
This area should include any disclaimers, acknowledgements, funding, or other information that would prevent a blind review. This information will not be available to reviewers during the review process.

ABSTRACT LENGTH AND IMAGES

Abstracts may contain a maximum of 800 words.

1 to 3 images in jpg format may be included.

Data tables must be uploaded as one of three possible images and not included in the abstract text boxes.
ENCORE PRESENTATIONS
AAPS accepts encore presentations, which are unpublished abstracts and posters that have been presented elsewhere. No abstract or resulting poster may be displayed at the National Biotechnology Conference or any other AAPS event without the review and approval of the NBC Abstract Screening Committee, regardless of prior presentation elsewhere.

ABSTRACT REVISIONS
- Revisions can be made at any time before the poster abstract submission deadline listed under the important dates.
- If you revise your abstract submission, you must be sure to save your changes and click Submit. Failure to complete all the steps will result in an incomplete submission, and your abstract will not be sent to the Abstract Screening Committee. Revisions cannot be made after the poster abstract submission deadline.
- Author names, affiliations, and company names will be published as submitted. Be sure you have the correct and current author information. No changes may be made after the submission deadline, including adding or removing authors.
- Proofread, spell-check, and make sure all authors are listed on your abstract before submitting. Abstracts will be presented in conference materials exactly as they appear at the time of submission.

NOTIFICATION OF RECEIPT AND VERIFICATION OF SUBMISSION
- You will receive an immediate email confirmation of completion when you have successfully submitted the abstract. This notification only confirms receipt of your submission and is not a notification of acceptance.
- If you do not receive an immediate email confirmation, your submission is not complete. You must return to the submission site to complete the submission process.
- If you return to the submission site to review or make changes to your abstract for any reason, you must complete all submission steps again in order to be sure your abstract is successfully submitted.

TOP 4 REASONS ABSTRACTS ARE REJECTED
Each year, AAPS rejects a few dozen abstracts – many “without review,” which means the abstracts were not qualified for consideration and were never shown to a panel of scientific screeners.

1. The abstract did not contain any data.
   AAPS will not accept an abstract that is not based on data that has already been developed.

2. The abstract is too commercial.
   AAPS welcomes the research conducted by any scientist, but it does not permit sales pitches.

3. The abstract does not follow the formatting and guidelines outlined in this document.

4. The abstract contained author, company name, or affiliation, preventing a blind review process.
APPEALS

Appeals based on proposed additions or changes to an abstract or poster that has already been submitted will be rejected without consideration by AAPS as these changes constitute a new abstract or poster.

To appeal the rejection or withdrawal of an abstract or poster, the submitting author must email the following to appeals@aaps.org within 5 business days of AAPS issuing the rejection:

1. Email Subject Line: Appeal [Abstract Submission ID Number]
2. Abstract title
3. Contact information for the submitter
4. Statement explaining on what grounds the author feels AAPS should reverse its decision

Appeals submitted by someone other than the submitter of the abstract, or by any means other than stated above, do not constitute an appeal and will be rejected without review.

Upon receiving a request for an appeal, the NBC Abstract Screening Committee Chair will seat a Review Committee of three members. The Review Committee will:

1. Consider the policies and requirements for abstracts and posters as described in AAPS’ materials
2. Review the abstract as submitted
3. Review the reasoning behind the rejection
4. Review the argument provided by the submitting author

The Review Committee will not consider any proposed changes to the abstract as submitted.

The final decision will be communicated to the author by email.
REGISTRATION REQUIREMENT
If selected for presentation, authors presenting posters must:

- Register as a full-conference, one-day, exhibitor, or exhibit-hall-only attendee for the 2022 AAPS National Biotechnology Conference by midnight ET on the presenting author registration deadline listed under important dates.
- The posters of authors who fail to register by the deadline will be withdrawn from AAPS' collection of posters.
- Coauthors may present in place of the presenting author if notification is made to AAPS at abstracts@aaps.org. The presenting coauthor must complete and pay for their registration before the change in presenting author can be made.
- A presenter who is not an author or coauthor of the abstract may present the poster if no authors are able to participate. Changes in the presenter or presenting author must be sent to AAPS at abstracts@aaps.org.
- Authors working in an exhibitor's booth may register as an exhibitor, but their registration must be completed by midnight ET on the presenting author registration deadline indicated under important dates.

CHANGE IN PRESENTING AUTHOR
All requests for a change in presenter or presenting author after the final submission deadline must be sent by the submitting author to AAPS at abstracts@aaps.org and include the Submission ID Number as well as the name and email address of the new presenter or presenting author. No authors may be added after the submission deadline.

POSTER SCHEDULE
AAPS will notify presenting authors of the scheduled day, time, and assigned poster number by email.

- If you do not receive notification, contact AAPS at abstracts@aaps.org for an update on the scheduling of your abstract.
- Notifications will be sent only to the designated presenting author.
- All posters will be included in the collection and available in the online platform.

CANCELLATION POLICY AND SUBSTITUTION
- All requests for refunds and/or substitutions must be submitted in writing and emailed to meetings@aaps.org.
- If you cancel your registration on/before March 31, 2022, you will be refunded your registration fee minus an administration fee of $100 for members/non-members, or $50 for students/postdocs members.
- No refunds will be given for “no shows” or for cancellations received on or after April 1, 2022.
- Refunds will be credited back to the original credit card used for payment.
- Substitutions from the same company may be submitted in writing at any time without penalty. If the membership status of the substitute differs from that of the original registrant, a refund or additional charge at the current rate may apply.
- Membership cancellation requests must be sent in writing by email to membership@aaps.org within 30 days of the membership start date. AAPS membership is non-transferrable and this offer is not valid if you have taken advantage of discounted member pricing during your current membership term.

ABSTRACT/POSTER WITHDRAWAL
The submitting author may withdraw their abstract or poster at any time.
To withdraw, send written notification to abstracts@aaps.org, and include:

1. Submission ID Number (Assigned Poster Number if withdrawing after poster schedule is issued)
2. Abstract title
3. Names of authors
4. Contact information for the submitter

AAPS will acknowledge all withdrawal notifications by email.
Withdrawal is not complete until AAPS issues notification of withdrawal to the submitting author.
Authors must format their posters using one of the PowerPoint templates AAPS will provide. Templates include instructions and format policies that must be followed in order to have a poster accepted for presentation.

The poster title must match the accepted abstract word-for-word/verbatim. No edits or changes are permitted.

The poster must describe all the methods used and data generated by the research. Omitting data from a poster that was described in the abstract is an ethical violation that may result in the poster being removed and the author, and the organization represented by the author, being barred from future meetings.

Authors of accepted abstracts and posters will abide by the decisions and instructions of AAPS. In the event that authors fail to follow AAPS’ policies and instructions, their posters will be removed from AAPS’ online collection. Authors may also have their acceptance rescinded and, in extreme cases, may see themselves, and the organizations they represent, barred from future meetings.

Posters must be uploaded by April 13, 2022. AAPS recommends uploading posters as soon as they are complete. All posters are reviewed prior to display by AAPS to ensure proper formatting.

Do I have to be a member of AAPS to submit an abstract?
No. Membership is not required.

Can a paper previously presented be submitted?
Encore presentations are acceptable and do not need to be referenced as an Encore presentation. Previously published research is not allowed.

Who owns the copyright on the abstract and poster?
The author(s)* maintains copyright of the abstract and poster, including all proprietary rights other than copyrights, such as patent rights.

*The submitting author is responsible for all authors knowing that their names appear on the abstract.

How will AAPS use my abstract?
If the abstract is accepted for poster presentation at the conference, the abstract will be displayed on the conference website/mobile app before, during, and after the meeting for a limited amount of time and on the AAPS member website after the conference.

How will AAPS use my poster?
Posters, including the abstract text, data, and graphics, will be available to all conference registrants on-site throughout the meeting, and online to registrants and AAPS members for a limited time after the meeting.

Will my poster be on the app or in the Proceedings?
Your abstract and poster will appear in the conference website, available to registrants only, and will be available on the AAPS website for members-only viewing after the meeting.
The 2022 AAPS National Biotechnology Conference has three tracks—each track has three themes.

**SUBMITTED ABSTRACTS MUST RELATE TO A TRACK!**

**IMPORTANT NOTE:** In the submission site, the structure below—Track/Theme/Keywords—are referred to as Review Groups. You will be prompted to select the Review Group that best fits your abstract. For screener applications, you will choose all that apply to your expertise.

**REVIEW GROUP (Track/Theme/Keywords) SELECTION PROCESS**

1. Select the TRACK that best fits your research:
   - COVID LEARNINGS
   - NEW AND UNUSUAL MODALITIES
   - WELL-CHARACTERIZED BIOLOGICALS AND BIOSIMILARS; POST-LICENSURE ISSUES

2. Select the THEME.

3. Select the KEYWORDS that best fits your research.

<table>
<thead>
<tr>
<th>TRACK</th>
<th>THEME</th>
<th>KEYWORDS</th>
</tr>
</thead>
</table>
| TRACK 1 Covid Learnings | THEME 1: Speed To Patient | - Accelerated Development  
- Essential Medicines  
- Vaccines  
- Innovation  
- Regulatory  
- Emergency Use Authorization  
- Benefit-Risk  
- Clinically Relevant |
| TRACK 1 Covid Learnings | THEME 2: Managing Collateral Damage | - Supply Chain  
- Ingredients  
- Formulation  
- Outsourcing  
- Comparability  
- Manufacturing Innovation  
- On-Demand Manufacturing  
- Continuous Manufacturing  
- New Materials  
- Global Distribution  
- Patient Access |

*continued on following page*
<table>
<thead>
<tr>
<th>TRACK</th>
<th>THEME</th>
<th>KEYWORDS</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRACK 1</td>
<td><strong>THEME 3:</strong></td>
<td>- Adaptive Design</td>
</tr>
<tr>
<td></td>
<td>Clinical Trials</td>
<td>- Accelerated Development</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Formulation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- mRNA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Nanoparticle Delivery Systems</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- COVID</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Pandemic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Decentralized Clinical Trials</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Risk-Benefit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Decision Trees</td>
</tr>
<tr>
<td>TRACK 2</td>
<td><strong>THEME 1:</strong></td>
<td>- AAV</td>
</tr>
<tr>
<td></td>
<td>Gene Therapies, Gene Editing, CAR-T</td>
<td>- Lipid Nanoparticle</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- mRNA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- CRISPR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Genetically Defined Diseases</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Cell Therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Gene Therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Regulatory</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- New Technologies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Cytokine Release Syndrome (CRS)</td>
</tr>
<tr>
<td>TRACK 2</td>
<td><strong>THEME 2:</strong></td>
<td>- Immuno-Oncology</td>
</tr>
<tr>
<td></td>
<td>Cell Therapies, Complex</td>
<td>- Hematological Malignancies</td>
</tr>
<tr>
<td></td>
<td>and Combination Products</td>
<td>- Oncology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Combination Therapies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Cell Therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- T Cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Natural Killer (NK) Cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Tumor Infiltrating Lymphocytes (TIL)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Hematopoietic Stem Cells (HSC)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Chimeric Antigen Receptor (CAR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Genetic Engineering</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Autologous</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Allogenic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Antibody-Oligo Conjugates</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Precision Exosomes</td>
</tr>
<tr>
<td>TRACK 2</td>
<td><strong>THEME 3:</strong></td>
<td>- Manufacturing</td>
</tr>
<tr>
<td></td>
<td>Drug/Device Combinations, Patient-</td>
<td>- Genetic Engineering</td>
</tr>
<tr>
<td></td>
<td>Individualized Approaches, Digital</td>
<td>- Immunosuppression</td>
</tr>
<tr>
<td></td>
<td>Components? Managing the Sample and</td>
<td>- Patient Centricity</td>
</tr>
<tr>
<td></td>
<td>Testing Chain</td>
<td>- Decentralized Clinical Trials</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Graph-vs-Host Disease (GvHD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Critical Quality Attributes (CQA)</td>
</tr>
</tbody>
</table>

continued on following page
<table>
<thead>
<tr>
<th>TRACK</th>
<th>THEME</th>
<th>KEYWORDS</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRACK 3</td>
<td>THEME 1: Vaccines</td>
<td>- Life Cycle Management&lt;br&gt; - Risk-Based Approaches&lt;br&gt; - New Adjuvants and Excipients&lt;br&gt; - Nucleic Acid-Based Vaccines&lt;br&gt; - Lipid Nanoparticles&lt;br&gt; - Clinically Relevant</td>
</tr>
<tr>
<td>TRACK 3</td>
<td>THEME 2: Biosimilars, Interchangeable Biologics and Well-Characterized Products</td>
<td>- Standards&lt;br&gt; - Comparability&lt;br&gt; - Product Characterization&lt;br&gt; - Critical Quality Attributes Release Specifications&lt;br&gt; - Protein Therapeutics&lt;br&gt; - Monoclonal Antibodies&lt;br&gt; - Glycoproteins</td>
</tr>
<tr>
<td>TRACK 3</td>
<td>THEME 3: New Assays</td>
<td>- Assay Innovation&lt;br&gt; - Comparability Challenges&lt;br&gt; - Clinically Relevant Immunogenicity&lt;br&gt; - Comparability&lt;br&gt; - Assay Transfer&lt;br&gt; - Compendial Updates</td>
</tr>
</tbody>
</table>